New plague vaccine trial aims to protect against deadly infection

NCT ID NCT07207408

Recruiting now ⭐️ VACCINE ⭐️ Sponsor: Dynavax Technologies Corporation Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 24, 2026 · Updated 22 times

Summary

This study tests a new vaccine called rF1V-1018 to see if it is safe and triggers a strong immune response against pneumonic plague, a serious lung infection caused by Yersinia pestis bacteria. About 148 healthy adults aged 18 to 55 will receive the vaccine and be monitored for side effects and antibody levels. The goal is to find a way to prevent plague after exposure through the air.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREVENTION OF PNEUMONIC PLAGUE RESULTING FROM AEROSOL EXPOSURE TO YERSENIA PESTIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

AMR- El Dorado
RECRUITING

El Dorado, Kansas, 67042, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
AMR- Las Vegas
RECRUITING

Las Vegas, Nevada, 889119, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
AMR- Miami
NOT_YET_RECRUITING

Miami, Florida, 33134, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PREVENTION OF PNEUMONIC PLAGUE RESULTING FROM AEROSOL EXPOSURE TO YERSENIA PESTIS